Physician profile
Taylor E Senko
NPI 1184311383
$508.63
in general payments reported to CMS, 2019-2025
13 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $253 · 2024: $113 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $158.41 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Idorsia Pharmaceuticals US INC | $78.87 | 2023 | Quviviq |
| Boston Scientific Corporation | $40.76 | 2023-2025 | General - Pain Management |
| Abbvie INC. | $36.54 | 2024 | |
| Lilly USA, LLC | $33.80 | 2023 | Mounjaro |
| Sanofi Pasteur INC. | $30.47 | 2025 | |
| Astellas Pharma US INC | $23.07 | 2023 | Veozah |
| Pfizer INC. | $22.50 | 2023 | |
| Abbott Laboratories | $18.66 | 2024 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $18.36 | 2025 | Auvelity |
| Amgen INC. | $17.40 | 2024 | Repatha |
| Merck Sharp & Dohme LLC | $16.24 | 2025 | Capvaxive, M-M-R II |
| Dexcom, INC. | $13.55 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Senko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.